A-FABP and oestrogens are independently involved in the development of breast cancer

References

• Hotamisligil GS, Bernlohr DA. Metabolic functions of FABPs–mechanisms and therapeutic implications. Nat Rev Endocrinol. 2015;11:592–605.
   PubMed Web of Science ®Google Scholar
• Storch J, Corsico B. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr. 2008;28:73–95.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hao J, Zeng J, et al. Epidermal FABP prevents chemical-induced skin tumorigenesis by regulation of TPA-induced IFN/p53/SOX2 pathway in keratinocytes. J Invest Dermatol. 2018;138:1925–1934.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Q, Rao E, et al. Epidermal Fatty Acid binding protein promotes skin inflammation induced by high-fat diet. Immunity. 2015;42:953–964.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun Y, Rao E, et al. Fatty acid-binding protein E-FABP restricts tumor growth by promoting IFN-beta responses in tumor-associated macrophages. Cancer Res. 2014;74:2986–2998.
   PubMed Web of Science ®Google Scholar
• Hao J, Yan F, Zhang Y, et al. Expression of Adipocyte/Macrophage Fatty Acid-Binding Protein in Tumor-Associated Macrophages Promotes Breast Cancer Progression. Cancer Res. 2018;78:2343–2355.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Rao E, Zeng J, et al. Adipose Fatty Acid Binding Protein Promotes Saturated Fatty Acid-Induced Macrophage Cell Death through Enhancing Ceramide Production. J Immunol. 2017;198:798–807.
   PubMed Web of Science ®Google Scholar
• Hao J, Zhang Y, Yan X, et al. Circulating Adipose Fatty Acid Binding Protein Is a New Link Underlying Obesity-Associated Breast/Mammary Tumor Development. Cell Metab. 2018;28:689–705 e685.
   PubMed Web of Science ®Google Scholar
• Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol. 2013;75:225–240.
   PubMed Web of Science ®Google Scholar
• Rock CL, et al. Favorable changes in serum estrogens and other biological factors after weight loss in overweight and obese breast cancer survivors. Clin Breast Cancer. 2013;13:188–195.
   PubMed Web of Science ®Google Scholar
• Ruggiero RJ, Likis FE. Estrogen: physiology, pharmacology, and formulations for replacement therapy. J Midwifery Womens Health. 2002;47:130–138.
   PubMed Web of Science ®Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(Suppl 1):3–63.
   PubMed Web of Science ®Google Scholar
• Hornstein TM, Schwerin JL. Menopause. In: Biology of Women, 5th Edition. Cengage Learning. 2012. p. 367–386.
   Google Scholar
• Kim C, Harlow SD, Zheng H, et al. Changes in androstenedione, dehydroepiandrosterone, testosterone, estradiol, and estrone over the menopausal transition. Womens Midlife Health. 2017;3. DOI:10.1186/s40695-017-0028-4.
   Google Scholar
• Bulun SE, Zeitoun K, Sasano H, et al. Aromatase in aging women. Semin Reprod Endocrinol. 1999;17:349–358. .
   PubMedGoogle Scholar
• Mesiano S. Roles of estrogen and progesterone in human parturition. Karger; 2001. p. 86–90.
   Google Scholar
• Rueda C, Osorio AM, Avellaneda AC, et al. The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. Climacteric. 2017;20:321–330.
   PubMed Web of Science ®Google Scholar
• Lemon HM, Wotiz HH, Parson L, et al. Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. JAMA. 1966;196:1128–1136.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H, Lippert TH. Estradiol metabolism and malignant disease. Maturitas. 2002;43:1–10.
   PubMed Web of Science ®Google Scholar
• Rudali G, Apiou F, Muel B. Mammary cancer produced in mice with estriol. Eur J Cancer. 1975;11:39–41.
   PubMed Web of Science ®Google Scholar
• Rosner B. Fundamentals of Biostatistics, 7th Edition. Cengage learning. 2010, p. 849.
   Google Scholar
• Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res Treat. 2002;4:133–136.
   Google Scholar
• Ali ES, Mangold C, Peiris AN. Estriol: emerging clinical benefits. Menopause. 2017;24:1081–1085.
   PubMed Web of Science ®Google Scholar
• Brusselaers N, Tamini RM, Konings P, et al. Different menopausal hormone regimens and risk of breast cancer. Ann Oncol. 2018;29:1771–1776.
   PubMed Web of Science ®Google Scholar
• Diet, Nutrition, Physical Activity and Breast Cancer. World Cancer Research Fund (WCRF)/American Institute of Cancer Research (AICR) Continuous Update Project. 2018, p.124.
   Google Scholar
• Key TJ, Wang DY, Brown JB, et al. A prospective study of urinary oestrogen excretion and breast cancer risk. Br J Cancer. 1996;73:1615–1619.
   PubMed Web of Science ®Google Scholar
• Mamillapalli R, Kayani J, Huttler J, et al. Estriol (E3) exposure during pregnancy and alered mammary gland cancer-associated gene expression. Reprod Sci. 2019;26(S1):109A.
   PubMedGoogle Scholar
• Lonning PE, Haynes BP, Dowsett M. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. Eur J Cancer. 2014;50:1055–1064.
   PubMed Web of Science ®Google Scholar